More awareness, more funding for research, and more entrepreneurship
MD Europe focuses on 3 areas
MORE AWARENESS FOR MD
Even though a great many people have MD, it is unknown to both the general public and healthcare providers. This has an enormous impact: patients are often diagnosed (too) late, don’t receive the right care, and there isn’t enough funding for a solution to MD. We are taking important steps to raise awareness through campaigns (“This will be the last generation with MD”), fundraisers, events, and more.
MORE FUNDING FOR RESEARCH
Structurally more funding is what the fight against MD needs right now, which is why donors are so important. For awareness and for taking concrete steps toward the last generation with MD.
MORE ENTREPRENEURSHIP
We want to accelerate drug development for MD. MD Netherlands has established a Venture Committee for this purpose, aimed at supporting researchers with scientific technology throughout the long process of drug development.
Scientific research
There is only one way to rid the world of MD: scientific research into the treatment of MD. MD Netherlands raises donations and funds for this scientific research and for projects that help make medication available more quickly for people with MD.
Donate directly
Project ANIQ:
Faster medication for children
Named after a real child with MD. She is cheerful, enthusiastic and, perhaps like her father, a bit naive and young for her age. Although she herself isn’t aware of what’s going on, she is experiencing more and more complaints: she is a heart patient and finds learning difficult, and her intestinal problems are increasingly affecting her too. The fear is of MD’s further progression.
There are a great many children (0-18 years old) like her; just as with adults, it’s vitally important that they receive medication as soon as possible to stop the deterioration and, hopefully, even improve their situation.
Children with MD not only have the most severe form of the disease, but also the most complex. Unlike adults with MD, the course of the disease in children has never been precisely described. The problem is that this also makes it impossible to demonstrate that a medication works. If that can’t be proven, medication doesn’t get approved, isn’t reimbursed, and moreover it remains unclear how medication should be adjusted for children. Project ANIQ is going to create that data. This will make it possible for medication already being tested on adults to become available for children too, in an adapted form. There is no more direct link between research and the availability of medication for a large group of severely ill children. For this project, MD Netherlands has brought together 7 universities and 5 pharmaceutical companies who will be working on this in the coming years.
Donate here for project ANIQ